A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850,...

Oncotarget 2017 / 12 Vol. 8; Iss. 67

A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

Zhang, Nannan, Zhang, Guo, Liu, Ning, Lin, Wanting, Ji, Sen, Zheng, Mingwu, Chen, Kai, Liang, Xiao, Li, Guobo, Ma, Yu, Zhu, Jun, Niu, Ting, Li, Lin-Li, Li, Jiong, Wei, Yu-Quan, Yang, Sheng-Yong
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Language:
english
Journal:
Oncotarget
DOI:
10.18632/oncotarget.22847
Date:
December, 2017
File:
PDF, 14.55 MB
english, 2017
Conversion to is in progress
Conversion to is failed